$233.85
-2.10[-0.89%]
At close: Apr 26
$233.85
0[0.00%]
After Hours: 4:00PM EDT
United Therapeutics
(NASDAQ:UTHR)Latest News for United Therapeutics Stock (NASDAQ:UTHR)
United Therapeutics Stock (NASDAQ: UTHR)
Categories: All
Wednesday, April 24, 2024
Tuesday, March 26, 2024
Monday, March 25, 2024
Thursday, February 22, 2024
- Beyond The Numbers: 4 Analysts Discuss United Therapeutics StockBenzinga Insights - Feb 22, 2024, 9:00AM
- Wedbush Reiterates Outperform on United Therapeutics, Maintains $308 Price TargetBenzinga Newsdesk - Feb 22, 2024, 8:22AM
- HC Wainwright & Co. Reiterates Buy on United Therapeutics, Maintains $300 Price TargetBenzinga Newsdesk - Feb 22, 2024, 6:48AM
Wednesday, February 21, 2024
- United Therapeutics' Challenges FDA Over Liquidia's Drug Approval Process, Clocks Strong Q4 EarningsVandana Singh - Feb 21, 2024, 1:17PM
- United Therapeutics Q4 GAAP EPS $4.36 Beats $4.19 Estimate, Sales $614.70M Beat $575.87M EstimateBenzinga Newsdesk - Feb 21, 2024, 6:01AM
- United Therapeutics Has Commenced Litigation Related To The FDA Inappropriately Denying United Therapeutics' Right To Obtain Stay Of Liquidia's Final Approval Until United Therapeutics' Pending Patent Infringement Claim Against Liquidia Can Be ResolvedBenzinga Newsdesk - Feb 21, 2024, 5:59AM
- Earnings Scheduled For February 21, 2024Benzinga Insights - Feb 21, 2024, 5:09AM
Tuesday, February 20, 2024
Monday, February 12, 2024
- This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run RatePriya Nigam - Feb 12, 2024, 11:00AM
- Teva Pharmaceutical To Rally Around 58%? Here Are 10 Top Analyst Forecasts For MondayAvi Kapoor - Feb 12, 2024, 7:43AM
- Goldman Sachs Upgrades United Therapeutics to Neutral, Raises Price Target to $215Benzinga Newsdesk - Feb 12, 2024, 5:16AM
Monday, February 05, 2024
Tuesday, January 23, 2024
Wednesday, December 20, 2023
- Liquidia Says Federal Circuit Affirmed Earlier PTAB Decision To Invalidate All Claims Of United Therapeutics Patent No. 10,716,793 ('793 Patent)Benzinga Newsdesk - Dec 20, 2023, 4:58PM
- Why Is Pulmonary Hypertension-Focused Liquidia Stock Soaring Today?Vandana Singh - Dec 20, 2023, 2:04PM
- United Therapeutics shares are trading lower after the company lost a patent case against Liquidia.Benzinga Newsdesk - Dec 20, 2023, 1:50PM
- Liquidia Wins Patent Case Against United Therapeutics; Federal Circuit Says "We Have Considered UTC's Remaining Arguments And Find Them Unpersuasive. For The Reasons Provided Above, We Affirm The Board's Unpatentability Determination"Benzinga Newsdesk - Dec 20, 2023, 10:17AM
Monday, December 04, 2023
Thursday, November 02, 2023
- JP Morgan Maintains Overweight on United Therapeutics, Raises Price Target to $294Benzinga Newsdesk - Nov 2, 2023, 5:24PM
- Morgan Stanley Maintains Overweight on United Therapeutics, Lowers Price Target to $314Benzinga Newsdesk - Nov 2, 2023, 3:19PM
- Wedbush Maintains Outperform on United Therapeutics, Raises Price Target to $308Benzinga Newsdesk - Nov 2, 2023, 9:15AM
Wednesday, November 01, 2023
Monday, October 30, 2023
- Health Care Company United Therapeutics Announces Acquisition of Miromatrix MedicalBenzinga Insights - Oct 30, 2023, 11:10AM
- Why Is Life Sciences Company Miromatrix Medical Stock Trading Higher Today?Vandana Singh - Oct 30, 2023, 10:03AM
- Why Biophytis Shares Are Trading Higher By Over 12%: Here Are 20 Stocks Moving PremarketLisa Levin - Oct 30, 2023, 8:44AM
- United Therapeutics Agrees To Buy Miromatrix Medical For $3.25/Share In Cash (An Aggregate Of ~$91M) And An Additional $1.75/Share In Cash Upon The Achievement Of A Clinical Development MilestoneBenzinga Newsdesk - Oct 30, 2023, 6:03AM
Friday, September 22, 2023
Thursday, August 03, 2023
- What 4 Analyst Ratings Have To Say About United TherapeuticsBenzinga Insights - Aug 3, 2023, 1:00PM
- From Benzinga's Biotech Conference: Wedbush Securities VP, Equity Research Andreas Argyrides Says 'Wedbush's Three Top Picks Of The Year Is Ascendis Pharma, Verona Pharma, And United Therapeutics'Benzinga Newsdesk - Aug 3, 2023, 12:01PM
- Morgan Stanley Maintains Overweight on United Therapeutics, Raises Price Target to $318Benzinga Newsdesk - Aug 3, 2023, 11:49AM
- Ladenburg Thalmann Maintains Buy on United Therapeutics, Raises Price Target to $268Benzinga Newsdesk - Aug 3, 2023, 9:28AM
- Wedbush Maintains Outperform on United Therapeutics, Raises Price Target to $307Benzinga Newsdesk - Aug 3, 2023, 8:07AM
- HC Wainwright & Co. Reiterates Buy on United Therapeutics, Maintains $300 Price TargetBenzinga Newsdesk - Aug 3, 2023, 6:28AM